Expression of the SLAM Family of Receptors Adapter EAT-2 as a Novel Strategy for Enhancing Beneficial Immune Responses to Vaccine Antigens

Yasser A. Aldhamen, Daniel M. Appledorn, Sergey S. Seregin, Chyong-jy J. Liu, Nathaniel J. Schuldt, Sarah Godbehere, and Andrea Amalfitano

Recent studies have shown that activation of the signaling lymphocytic activation molecule (SLAM) family of receptors plays an important role in several aspects of immune regulation. However, translation of this knowledge into a useful clinical application has not been undertaken. One important area where SLAM-mediated immune regulation may have keen importance is in the field of vaccinology. Because SLAM signaling plays such a critical role in the innate and adaptive immunity, we endeavored to develop a strategy to improve the efficacy of vaccines by incorporation of proteins known to be important in SLAM-mediated signaling. In this study, we hypothesized that coexpression of the SLAM adapter EWS-FLI1–activated transcript 2 (EAT-2) along with a pathogen-derived Ag would facilitate induction of beneficial innate immune responses, resulting in improved induction of Ag-specific adaptive immune responses. To test this hypothesis, we used rAd5 vector-based vaccines expressing murine EAT-2, or the HIV-1–derived Ag Gag. Compared with appropriate controls, rAd5 vectors expressing EAT-2 facilitated bystander activation of NK, NKT, B, and T cells early after their administration into animals. EAT-2 overexpression also augments the expression of APC (macrophages and dendritic cells) surface markers. Indeed, this multitiered activation of the innate immune system by vaccine-mediated EAT-2 expression enhanced the induction of Ag-specific cellular immune responses. Because both mice and humans express highly conserved EAT-2 adapters, our results suggest that human vaccination strategies that specifically facilitate SLAM signaling may improve vaccine potency when targeting HIV Ags specifically, as well as numerous other vaccine targets in general. The Journal of Immunology, 2011, 186: 000–000.
tyrosine residues directly located in their short C-terminal tails (17). In contrast, the SAP adapter regulates SLAM signaling by recruiting the protein tyrosine kinase FynT.

Various reports indicate a possible role for the binding of SLAM (CD150) receptor in the immunological synapse, whereby SLAM receptor activation acts as a costimulatory molecule facilitating the activation of dendritic cells (DCs) and macrophages. For example, in CD40L-activated human DCs, Ab-mediated ligation of SLAM receptor augmented the secretion of proinflammatory cytokines such as IL-12 and IL-8, but not IL-10 (18). Furthermore, the SLAM receptor was also found to play a role in the production of IL-6 and IL-12 by mouse peritoneal macrophages (19). In addition, macrophages derived from SLAM-deficient mice show a marked reduction in secretion of IL-12, TNF, and NO (19). Because EAT-2 is the only known SLAM-associated adapter protein expressed in DCs and macrophages, it has been proposed that EAT-2 facilitates SLAM-dependent proinflammatory cytokine expression in these cell types (16).

Relative to vaccine augmentation strategies, we note that the TLR adapter MyD88 also facilitates cytokine gene expression during TLR-dependent signaling and that overexpression of MyD88 from DNA-based vaccines facilitated the induction of Ag-specific adaptive immune responses by the vaccine platform (20, 21). Based on these facts, we hypothesized that expression of EAT-2 from a vaccine platform could also augment innate immune responses, potentially resulting in improved APC functions in vivo and consequently improvement in the induction of adaptive immune response generated against a coexpressed target Ag. In this study, we confirmed that an adenovirus (Ad)-based vaccine expressing the SLAM adapter molecule EAT-2 facilitates the induction of several arms of the innate immune system and that these inductions positively correlate with an improved ability of the vaccine to induce stronger cellular immune responses to a coexpressed Ag. Our results highlight for the first time, to our knowledge, the use of a SLAM immune regulatory pathway component to improve vaccination efficacy.

Materials and Methods

Vector construction

The Ad-GFP virus was purified as previously described (22). The open reading frame of EAT-2 gene (GenBank Accession no. NM_012009; http://www.ncbi.nlm.nih.gov/nuccore/14847581) was excised using primers flanked by XhoI and XbaI restriction endonucleases (NEB, Ipswich, MA) from a plasmid (Open Biosystem, Huntsville, AL) and subcloned into the pShuttle vector, which contains a CMV expression cassette. The resulting pShuttle-CMV-EAT2 shuttle plasmid was linearized with PmlI restriction enzyme and homologously recombined with the pAdEasy1 Ad5 vector genome as previously described (23) yielding pAd-EAT2. HEK293 cells were transfected with PacI linearized plasmid, and viable virus was obtained and amplified after several rounds of expanding infection. Ad-EAT2 virus was purified using a CsCl2 gradient as previously described (24). The titer obtained was ∼2.3 × 1010 virus particles (vp)/ml. Direct sequencing and restriction enzyme mapping were carried out to confirm the integrity of the EAT-2 sequence. To construct Ad-HIV/Gag, the HXB2 Gag gene (GenBank Accession no. K03455; http://www.ncbi.nlm.nih.gov/nuccore/1906382) was blunt-end subcloned into the EcoRV site of pShuttle-CMV. Recombination and viral propagation was completed as described above. EAT-2 and Gag expression was verified using Western blotting (data not shown).

Animal procedures

All animal procedures were approved by the Michigan State University (East Lansing, MI) Institutional Animal Care and Use Committee. Adult male C57BL/6 and BALB/c mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Intravenous injection of animals (8–10 wk old) consisted of injection (via the retroorbital sinus) of 200 μl of a PBS solution (pH 7.4), containing 7.5 × 1010 total virus particles of either Ad-GFP or Ad-EAT2 as previously described (25). Plasma and tissue samples were obtained and processed at the indicated times postinjection as previously described (25). Intramuscular injections were completed by injection of the indicated virus particles in a total volume of 20 μl into the tibialis anterior of the right hind limb.

Cytokine and chemokine analysis

A mouse 7-plex multiplex-based assay was used to determine the indicated cytokine/chemokine plasma concentrations per the manufacturer’s instructions (Bio-Rad, Hercules, CA) via Luminex 100 technology (Luminex, Austin, TX) essentially as previously described (25).

ELISPOT analysis

Splenocytes were harvested from individual mice, and RBCs were lysed using ACK lysis buffer (Invitrogen, Carlsbad, CA). Ninety-six-well MultiScreen high protein binding Immunoplate-96-well microplate (Millipore, Billerica, MA) were pretreated with ethanol, coated with mouse anti-IFN-γ or IL-2 capture Abs, incubated overnight, and blocked prior to the addition of 5 × 103 splenocytes/well. Ex vivo stimulation included the incubation of splenocytes in 100 μl medium alone (unstimulated) or medium containing 4 μg/ml Gag-specific peptides (Gag-AMQLMKT1 constructed by Genscript, Piscataway, NJ) or peptide no. QBI 304796 (obtained from QBI [Gathter, MD] through the National Cancer Institute Research Triangle Park, NC). HIV-1 (ATCC TIB71) were maintained in DMEM supplemented with 10% FBS and 5% CO2 incubator. 15mer Gag-specific peptides were obtained from the National Institutes of Health AIDS Reagent and Reference Program (Rockville, MD) (Cat no. 8117, Lot no. 9). Staining of plates was completed per the manufacturer’s protocol. Spots were counted and photographed by an automated ELISPOT reader system (Cellular Technology, Cleveland, OH). Ready-set-go IFN-γ and IL-2 mouse ELISPOT kits were purchased from eBioscience (San Diego, CA).

In vitro cell culture

Bone marrow cells were extracted from the femurs and tibiae of male 6- to 8-wk-old BALB/c mice, and red cells were removed using ACK lysis buffer (Invitrogen). Bone marrow cells were cultured in DMEM supplemented with 10% FBS and 3% supernatant derived from confluent L929 cell cultures. At day 7, immature macrophages were collected and plated into 12-well plates for 24 h. This procedure yields a pure population of M-CSF–dependent, adherent macrophages. Murine RAW264.7 macrophages (ATCC TIB71) were maintained in DMEM supplemented with 10% FBS and penicillin–streptomycin following standard procedures. Suspensions of 5 × 105 cells were seeded into each well of 12-well plates. Then, the cells were incubated with 1 ml culture medium alone or with medium containing Ad-EAT2 or Ad-GFP at the multiplicities of infection indicated for 72 h.

Cell staining and flow cytometry

To identify immune cells transduced by Ad-mediated gene transduction, splenocytes derived from Ad-GFP–injected mice were stained with the following Abs: allophycocyanycin-Cy7-C7-CD3, Alexa Fluor 700-CD8a, PE-Cy7-NK1.1, and allophycocyanin-CD11c. Splenocytes were then subjected to flow cytometry, and the percentages of Ad-GFP–transduced cells (FITC+) were calculated using FlowJo software. For innate immune cell activation studies, splenocytes were stained with various combinations of the following Abs: PE-CD69 (3 μg/ml), FITC-CD8a, allophycocyanin-CD3, allophycocyanin-Cy7-CD3, Alexa Fluor 700-CD8a, PerCP-Cy5.5-CD19, PE-Cy7-NK1.1, PE-Cy7-TNF-α, allophycocyanin–IFN-γ (4 μg/ml) (all obtained from BD Biosciences, San Diego, CA), and PerCP-Cy5.5–IL-2 (4 μg/ml) (BioLegend, San Diego, CA). For bone marrow–derived macrophage (BMDM) and RAW264.7 cell studies, the following Abs were used: allophycocyanin-CD80, V450-CD86 (BD Biosciences), Alexa Fluor 700–MHC class II, and FITC-CD40 (eBioscience). Cells were incubated on ice with the appropriate Abs for 30 min, washed, and sorted using an LSR-II flow cytometer and analyzed using FlowJo software. For intracellular cytokines staining, cells were surface stained, fixed with 2% formaldehyde (Polysciences, Warrington, PA), permeabilized with saponin (Sigma–Aldrich, St. Louis, MO), and stained for intracellular cytokines. We included the violet fluorescent reactive dye (VIVID; Invitrogen) as a viability marker to exclude dead cells from the analysis (26). Blood was isolated by retroorbital bleeds, and PBMCs were isolated using Lympholyte-Mammal (Cedarlane, Burlington, NC). Tetramer staining of PBMCs was completed using a PE-conjugated MHCl class I tetramer fol- lowed by the AMQLMKT1 peptide in the presence of EAT-2, pShuttle-CMV-EAT2, and the Health Tetramer Core Facility (Atlanta, GA). CD8+ T cells were depleted from pooled splenocyte preparations using MACS beads and LS columns per the manufacturer’s protocol (Miltenyi Biotec, Bergisch Gladbach, Germany).
%CD8^+ SFC = SFC CD8-dep/SFC CD8+. Depletion was verified using FACS analysis using allophycocyanin-CD8a and Pacific blue-CD4 Abs (BD Biosciences). FACS analyses revealed >96% depletion of CD8^+ T cells (Supplemental Fig. 4).

In vivo CTL assay
BALB/c or C57BL/6 mice were covaccinated with equivalent doses of Ad-HIV/Gag with either Ad-GFP or Ad-EAT2 (totaling 1 × 10^11 vp for BALB/c and 1 × 10^10 vp for C57BL/6 mice). At 14 d, syngeneic splenocytes were isolated and either pulsed with an irrelevant peptide specific to the Plasmodium falciparum circumsporozoite Ag (NYDNAGTNL) or with the HIV-Gag immunodominant AMQMLKETI peptide or QBI no. 304796 for 1 h at 37˚C. Irrelevant peptide-pulsed cells were subsequently stained with 1 μM CFSE (CFSELow) while Gag-peptides–pulsed cells were stained with 10 μM CFSE (CFSEHigh). Naive and immunized mice were injected with equivalent amount of both CFSELow and CFSEHigh stained cells via the retroorbital sinus. After 5 h, mice were terminally sacrificed, and splenocytes were recovered and sorted on an LSR-II flow cytometer. FlowJo software was used to determine percentages of CFSE-stained cells. %Specific killing = 1 − ([%CFSEHigh/%CFSELow]immunized/[%CFSEHigh/%CFSELow]mockinjected).

Detection of EAT-2 gene expression in vivo
To determine relative levels of EAT-2 and spleen-derived EAT-2 RNA transcript, spleen tissues were snap frozen in liquid nitrogen, and RNA was harvested from 100 mg frozen tissue using TRIzol reagent (Invitrogen) per the manufacturer’s protocol. After RNA isolation, reverse transcription was performed on 180 ng total RNA using SuperScript II (Invitrogen) reverse transcriptase and random hexamers (Applied Biosystems, Foster City, CA) per the manufacturer’s protocol. Reverse transcription reactions were diluted to a total volume of 60 μl and 2 μl was used as the template in the subsequent PCR reactions. Primers were designed using Primer Bank Web-based software (http://pga.mgh.harvard.edu/primerbank/). The following primers were used: forward primer (5’-9’-CTGGGACTGATCTCAGGGTG-3’9’) and reverse primer (5’-9’-GAAGGGAACGGGAGAATGGG-3’9’). Quantitative PCR was carried out on an ABI 7900HT Fast Real-
Time PCR System using SYBR Green PCR Mastermix (Applied Biosystems) in a 15-μl reaction. PCRs were subjected to the following procedure: 95°C for 10 min followed by 40 cycles of 95°C for 15 s followed by 60°C for 1 min. The comparative Ct method was used to determine relative gene expression using GAPDH to standardize expression levels across all samples. Relative expression changes were calculated based on comparing experimental levels of a respective spleen transcript with those quantified in spleen samples derived from mock-injected animals.

Statistical analysis

Statistically significant differences in toxicities associated with innate immune responses were determined using one-way ANOVA with a Student–Newman–Keuls post hoc test; \( p < 0.05 \) was deemed a statistically significant difference. \( *p < 0.05; **p < 0.01; ***p < 0.001; \#p < 0.001 \) (statistically different from mock injected animals).

**FIGURE 3.** Ad-EAT2–mediated activation of innate and adaptive immune cells in vivo. C57BL/6 mice \( (n = 4) \) were either mock injected or intravenously injected with \( 7.5 \times 10^{10} \) vp of either Ad-GFP or Ad-EAT2. CD69 expression by PBMC- \((A)\) and splenocyte- \((B)\) derived NK, NKT, CD3+CD8+, CD3+CD8\(^-\), and B cells was evaluated 6 h after virus injection. PBMCs and splenocytes were harvested, stained, and sorted on an LSR-II flow cytometer. The bars represent mean ± SD. Statistical analysis was completed using one-way ANOVA with a Student–Newman–Keuls post hoc test; \( p < 0.05 \) was deemed a statistically significant difference. *\( p < 0.05; **p < 0.01; ***p < 0.001; \#p < 0.001 \) (statistically different from mock injected animals).

**FIGURE 4.** HIV-Gag–specific cellular immune responses elicited by Ad-HIV/Gag and Ad-EAT2 coimmunization. BALB/c mice were coimmunized i.m. in the tibialis anterior with equivalent viral particles of Ad-HIV/Gag mixed with either Ad-GFP or Ad-EAT2 (total of \( 1 \times 10^7 \) vp mixed prior to injection). At 6 days postinjection (dpi), PBMCs \((A)\) were collected from the immunized mice and stained with a PE-conjugated H2-Kd-AMQMLKETI tetramer complex. At 14 dpi, mice were sacrificed and PBMCs \((B)\) or splenocytes \((C)\) were harvested and stained with a PE-conjugated H2-Kd-AMQMLKETI tetramer complex together with APC-conjugated anti-CD3 and FITC-conjugated anti-CD8 Abs. The bars represent mean ± SD for six mice per group (pool of two for PBMCs) for virus injected and three mice for naive animals. Statistical analysis was completed using one-way ANOVA with a Student–Newman–Keuls post hoc test; \( p < 0.05 \) was deemed a statistically significant difference. *\( p < 0.05; **p < 0.01 \) (statistically different from mock-injected animals).
with a Student–Newman–Keuls post hoc test was used. Data of all graphs in this article are presented as mean ± SD. GraphPad Prism software was used for statistical analysis.

**Results**

**EAT-2–expressing Ad vectors enhance Ad vector-induced innate immune responses in vivo**

We constructed an E1 and E3 deleted ([E1−])Ad vector specifically designed to express the murine homologue of the SLAM adapter protein EAT-2. These EAT-2–expressing Ad vectors were fully viable, grew to high titers, and were purified and quantified exactly as done for conventional [E1−]Ad vaccines (25). To analyze the maximal impact that Ad-EAT2 expression might have upon innate immune responses, we administered Ad-EAT2 into C57BL/6 mice and measured the levels of cytokines and chemokines in the plasma 6 h postinjection (hpi), a time point we have previously demonstrated to be when maximal induction of proinflammatory cytokines and chemokines occurs after Ad vector administration (9, 27, 28). Administration of the Ad-EAT2 vector into C57BL/6 mice resulted in induction of significantly higher plasma levels of RANTES and MCP-1 at 6 hpi as directly compared with those of mice injected identically and treated with an Ad-GFP control vector (Fig. 1). The levels of IL-6, IL-12p40, MIP-1b, KC, and G-CSF were also significantly induced by Ad-EAT2 vectors; however, these levels were not statistically different between Ad-EAT2 and Ad-GFP injected mice (Fig. 1).

**Administration of EAT-2–expressing Ad induces activation of innate immune cells**

To determine what innate immune cell types may be transduced by the Ad vectors expressing EAT-2 (and potentially be responsible for the enhanced cytokine responses noted in Fig. 1), we analyzed Ad vector transduction of several important classes of innate immune cells found in the spleen by flow cytometry. Using an Ad vector expressing a tracking Ag (GFP), we confirmed that Ad vectors can transduce DCs, NK cells, as well as low levels of T cells upon administration into mice (Fig. 2A–D). Notably, we found that the highest subset of DCs that was transduced by Ad-GFP vectors was CD11c+CD8α−, a distinct subset of DCs shown to play a critical role in shaping adaptive immune responses after vaccination (29) (Fig. 2A). Additionally, we confirmed that after identical administrations of the Ad-EAT2 vector, EAT-2 gene expression was occurring in spleen cells as well (Fig. 2E).

It is widely appreciated that Ads enhance innate immune cell effector functions (30, 31). To evaluate additionally the phenotype...
of immune cells after exposure or transduction by the Ad vector expressing EAT-2, we analyzed the expression of the lymphocyte activation marker CD69 as well as IFN-γ production in various immune cells shortly after administration of Ad-EAT2 into C57BL/6 mice. Our results confirmed that Ads, in general, significantly induce a rapid activation of NK and NKT cells in both PBMCs and splenocytes, as confirmed by the presence of increased percentages of CD69-expressing NK and NKT cells in Ad-GFP–treated mice (Fig. 3A, 3B). Specifically, injection of Ad-EAT2 induced significantly higher numbers of CD69-expressing NK and NKT cells, both in PBMCs and splenocytes at 6 hpi, compared with that for the Ad-GFP control vector (Fig. 3A, 3B). At 48 hpi, CD69 expression on NK cells remained significantly higher ($p < 0.05$) only in PBMCs derived from Ad-EAT2–injected mice compared with that of Ad-GFP–injected mice (Supplemental Fig. 1A). All other differences previously noted at 6 hpi had dissipated by 48 hpi (Supplemental Fig. 1C), suggesting that expression of EAT-2 by Ad vaccines transiently improves the induction of these responses.

Treatment with either Ad-EAT2 or Ad-GFP induced significantly elevated numbers of IFN-γ-expressing NK cells at both 6 and 48 hpi ($p < 0.001$ and $p < 0.05$, respectively). However, no significant differences were observed between the control and experimental viruses, suggesting that overexpression of EAT-2 cannot induce additional inductions of IFN-γ relative to the ability of the Ad vector itself (Supplemental Fig. 2). Finally, at 48 hpi, the number of NKT cells expressing CD69 was also significantly increased ($p < 0.05$) in PBMCs derived only from Ad-EAT2–injected mice (Supplemental Fig. 2A). CD69 expression on splenic NKT cells isolated from both Ad-EAT2– and Ad-GFP–injected mice were also both significantly ($p < 0.05$) increased over mock-injected mice (Supplemental Fig. 1C).

Administration of EAT-2–expressing Ads induces greater activation of adaptive immune cells

Because the SLAM family of receptors are expressed in various innate and adaptive immune cells (12) and the activation of T cells and/or B cells can be initiated or accentuated by innate immune system activation (7), we sought to analyze adaptive immune cell responses shortly after administration of Ad-EAT2. Our results confirmed that Ad vector administration in and of itself induces a rapid activation of CD3+CD8+ T cells, CD3+CD8− T cells, and B cells, Ad-dependent responses that can all be further accentuated with expression of EAT-2. For example, injection of Ad-EAT2 resulted in significantly higher numbers of splenic CD69-expressing CD3+CD8+ T cells ($p < 0.01$), CD3+CD8− T cells ($p < 0.01$), and B cells ($p < 0.001$) at 6 hpi (Fig. 3B) compared with the numbers of these cells being induced by the control Ad vector. At 48 hpi, the percentage of splenic CD69-expressing CD3+CD8+ T cells, CD3+CD8− T cells, and B cells derived from Ad-EAT2– and Ad-GFP–injected mice remained significantly higher ($p < 0.001$) over mock-injected mice; however, no statistical differences were observed between the control and experimental Ad viruses at this time point (Supplemental Fig. 1D). We also evaluated the percentage of CD69-expressing cells in PBMCs from the same animals. At 6 hpi, we observed a significantly ($p < 0.05$) higher percentage of CD69-expressing total lymphocytes (as defined previously) in Ad-EAT2–injected mice compared with that of Ad-GFP–injected mice. When analyzing specific lymphocyte subsets, we observed a significant increase in the percentage of CD69-expressing CD3+CD8− T cells isolated from Ad-EAT2–injected mice compared with the percentage of identical cells isolated from Ad-GFP–injected mice ($p < 0.05$) (Fig. 3A). Higher activation of CD3+CD8− T cells and B cells was observed in PBMCs derived from Ad-EAT2–injected mice.
compared with that of the mock-infected mice; however, no statistically significant differences in activation levels were observed between the control and experimental Ads in these cell types (Fig. 3A). By 48 hpi in PBMCs, any statistically significant differences between the control and experimental Ad vector-injected animals had resolved (Supplemental Fig. 1B).

**Ad vector expressing EAT-2 enhances T cell responses to a coadministered Ag**

Simultaneous administration of Ags with adjuvants can stimulate the innate immune system to improve significantly the adaptive immune responses to the antigenic target (32, 33). To investigate whether the enhanced innate immune responses promoted by Ad-mediated expression of EAT-2 could influence the adaptive immune responses to a coadministered Ag, we immunized BALB/c or C57BL/6 mice with both an Ad-based vector expressing the HIV-1 clade B Gag protein (HXB2) and the Ad-EAT2 vector or a control vector (Ad-GFP). We performed initial dose-curve studies to identify the lowest dose of Ad-HIV/Gag that generated detectable Gag-specific cellular immune responses in the two distinct strains of mice. As a result, we identified an Ad-HIV/Gag dose of $5 \times 10^6$ vp/mouse for BALB/c mice and $5 \times 10^8$ vp for C57BL/6 mice as the most relevant experimental doses for these studies (data not shown). Six days after BALB/c mice were i.m. injected with $5 \times 10^6$ Ad-HIV/Gag mixed with equivalent amounts of either the control Ad-GFP vector or Ad-EAT2, we were able to detect heightened Gag-specific, tetramer-positive CD8$^+$ T cells in PBMCs derived from mice coimmunized with Ad-HIV/Gag plus Ad-EAT2 compared with that of Ad-HIV/Gag plus Ad-GFP coimmunized mice (Fig. 4A). At 14 dpi, PBMCs ($p < 0.05$) and splenocytes ($p < 0.05$) derived from mice coimmunized with Ad-HIV/Gag plus Ad-EAT2 contained higher numbers of Gag-specific tetramer-positive CD8$^+$ T cells compared with that of the respective cell populations isolated from control mice (Fig. 4B, 4C). After ex vivo stimulation with the immunodominant Gag peptides AMQLMKETI (QBI no. 304754 for BALB/c mice) or QBI no. 304796 (for C57BL/6 mice), splenocytes derived from mice coimmunized with Ad-HIV/Gag and Ad-EAT2 contained significantly ($p < 0.001$) increased numbers of Gag-specific, IFN-γ–secreting cells (Fig. 5A, 5B, respectively). We also observed significantly increased numbers of IL-2–secreting, HIV-Gag peptide specific (QBI no. 304754) splenocytes derived from BALB/c mice coimmunized with Ad-HIV/Gag plus Ad-EAT2 compared with that of Ad-HIV/Gag plus Ad-GFP coimmunized mice ($p < 0.01$) (Fig. 5A).

**EAT-2 expression during HIV-Gag vaccination also facilitated a broadened induction of HIV-Gag–specific T cell clones**, as we observed increased numbers of Gag-specific IFN-γ– and IL-2–co secreting splenocytes responding to an expanded variety of HIV-Gag–specific peptides present within the full HIV-Gag protein (i.e., QBI no. 304742, 304769, 304779, 304800) and a peptide pool (304790, 403808, and 304826) (Fig. 6A, 6B). In a more global analysis of the extent of HIV-Gag peptide recognition promoted by prior expression of EAT-2, we ex vivo–stimulated splenocyte preparations derived from the immunized mice with HIV-gag–derived peptide pools, each pool containing two to four
Gag-specific 15mer peptides spanning the entire HIV-Gag protein sequence. We observed an increased breadth in the immune recognition of HIV-Gag by coexpression of EAT-2, as the number of HIV Gag-specific peptides that triggered cellular responses from splenocytes derived from the Ad-HIV/Gag plus Ad-EAT2 control mice (Supplemental Fig. 3). CD8 T cell depletion studies suggested that the majority of the T cells responding to the Ags were CD8+ (Supplemental Fig. 4).

Assessment of Gag-specific T cell cytokine responses by multiparameter flow cytometry

Published reports have shown that the increased presence of Ag-specific T cells that express several cytokines in response to Ags correlate with improved vaccine-induced protective immunity and positively correlate with the induction of long-lived memory responses (34, 35). To enumerate these “polyfunctional” T cells, we evaluated the expression of cytokines in HIV-Gag–specific CD8+ T cells generated after Ad-HIV/Gag and Ad-EAT2 coimmunization. Six-color flow cytometry was used to enumerate the frequency of CD8+ T cells producing IFN-γ, TNF-α, and/or IL-2 after ex vivo stimulation with HIV-Gag–specific peptides. We observed statistically higher numbers of HIV-Gag–specific IFN-γ positive (p < 0.05) (Fig. 7B, 7C) and IFN-γ/TNF-α double-positive (p < 0.05) (Fig. 7D, 7E) CD8+ T cells derived from Ad-HIV/Gag and Ad-EAT2 coimmunized mice compared with that of mice vaccinated with the control vaccines. When evaluating TNF-α or IL-2 single-positive CD8+ T cells, we also observed increased numbers of CD8+ T cells that express TNF-α or IL-2 derived from Ad-HIV/Gag and Ad-EAT2 coimmunized mice compared with that of Ad-HIV/Gag and Ad-GFP coimmunized mice; however, with these numbers of samples, these improved trends did not reach statistically significant levels (data not shown).

Cytotoxic CD8+ T cells from Ad-EAT2 coimmunized mice exhibit improved Gag-specific cytotoxicity in vivo

The direct measurement of in vivo functionality of CD8+ T lymphocytes (CTLs) to specifically kill Ag-presenting target cells provides a critical assessment as to their overall functional capacity. To evaluate the in vivo cytolytic activity of the Gag-specific CD8+ T lymphocytes generated after Ad-HIV/Gag and Ad-EAT2 coimmunization, mice were coimmunized with Ad-HIV/Gag plus Ad-EAT2 or Ad-HIV/Gag plus Ad-GFP. Fourteen days after vaccination, the two groups of mice were then injected with CFSE-labeled syngeneic splenocytes pulsed with the Gag-derived peptides AMQMLKETI or QBI no. 304796. The elimination of the peptide-pulsed splenocytes (CFSEhigh) was then examined by a flow cytometry-based CTL assay (36). Our results demonstrated that HIV-Gag–specific CTL activities induced in mice coimmunized with Ad-HIV/Gag and Ad-EAT2 were significantly higher compared with those of control mice (p < 0.05 for BALB/c and p < 0.01 for C57BL/6 mice) (Fig. 8A, 8B).

Ad vector expressing EAT-2 induces greater expression of CD40, CD80, CD86, and MHC class II molecules

To investigate the mechanisms underlying the enhanced Gag-specific adaptive immune responses generated after Ad-HIV/Gag and Ad-EAT2 coimmunization, we evaluated the expression of markers associated with APC function, in this instance analyzing BMDMs. Isolated BMDMs were initially infected with the Ad-EAT2 or Ad-GFP vectors at escalating multiplicities of infection (5,000–50,000 vp/cell). Cells were then analyzed for the surface expression of CD80 and CD86 costimulatory molecules by flow cytometry. Mock-infected BMDMs expressed low levels of CD80 and CD86, whereas infection with the control Ad virus significantly induced the expression of CD80 and CD86 molecules (Fig. 9). Notably, Ad-EAT2 infection greatly enhanced the expression of CD80 and CD86 compared with that of BMDMs infected with

FIGURE 9. EAT2 overexpression augments CD80 and CD86 expression by BMDMs. In vitro-cultured murine BMDMs (500,000 cells/well) were mock infected or infected with the Ad-EAT2 or Ad-GFP control for 72 h at the multiplicity of infection (MOI) shown. A, Expression of GFP on BMDMs after infection with escalating doses of Ad-GFP at 72 h. B, Expression of CD80 on BMDMs 72 hpi with escalating doses of Ad-EAT2 (black) or Ad-GFP (gray). C, CD86 expression in BMDMs infected with various doses of Ad-EAT2 or Ad-GFP at 72 hpi. Data are representative of three independent experiments with similar results. Samples were plated in triplicate and are expressed as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 (statistically different from uninfected cells).
the control Ad (Fig. 9). These effects were not seen if the BMDMs were infected with a UV irradiation-inactivated Ad-EAT2 vector, confirming that EAT-2 gene expression was necessary for the effect (data not shown). RAW264.7 cells were also infected with either the Ad-EAT2 or Ad control vector. Similar to the results we obtained in BMDMs, Ad infection resulted in significant increases in the expression of CD40, CD80, CD86, and MHC class II molecules (Fig. 10). Importantly, Ad-EAT2 infection resulted in significantly higher levels of CD40, CD80, CD86, and MHC class II molecules compared with those of cells infected with the Ad control virus (Fig. 10).

Discussion
The SLAM family of receptors modulate multiple innate and adaptive immune responses through their intracellular signaling adapters SAP, EAT-2, and ERT (12, 15, 16). This report provides evidence supporting an important new strategy to improve the efficacy of vaccines in general, and that of Ad-based vaccines specifically, by expression of SLAM system-derived adapters simultaneously with Ag-specific vaccinations. More specifically, in this study we confirmed these notions by using an Ad vaccine genetically engineered to express the SLAM adapter molecule EAT-2 along with the HIV-derived Ag Gag. The inclusion of the Ad-EAT2 vector in Ad-HIV-gag vaccine mixtures significantly impacted upon the innate immune responses induced by the vaccine mixture, and more importantly specifically improved multiple, Ag-specific adaptive (cellular) immune responses to the target Ag present in the vaccine mixture, in this instance the HIV Gag protein.

There are a number of mechanisms as to how expression of EAT-2 might facilitate induction of Ag-specific immune responses in vivo. NK cells represent a subset of innate immune cells that have been shown to play an important role in bridging innate and adaptive immune responses by influencing DC function (37), providing signals for augmenting Th1 immune responses (38–40), and inducing tumor-specific CTLs (41). In addition, it has been shown recently that NK cell-mediated cytolysis of Ag-expressing target cells induces robust Ag-specific adaptive immune responses (42). EAT-2 has been shown to be indispensable in activating NK cell-mediated cytolysis by acting as a downstream adapter protein facilitating signaling from the SLAM family receptor CRACC (in mice) (43, 44) or NTB-A (in humans) (45). Ad-mediated transduction of the EAT-2 gene enhanced NK cell activation (especially prolonged in those NK cells found in the circulation), activations that may facilitate the activation and/or maturation of DCs thereby biasing the HIV-Gag–specific immune profile toward a Th1 response (40). Of interest, we noted that Ads induced significantly elevated levels of IFN-γ in NK cells regardless of EAT-2 overexpression. These results suggest that EAT-2 overexpression enhances immune responses to the co-injected Ag in a mechanism that does not involve induction of higher levels of IFN-γ-producing NK cells. For example, in addition to NK cells,
we also observed increased activation of NKT cells after Ad-mediated transduction of the EAT-2 gene. Several reports have shown that enhancing the activation of NKT cells can also positively influence the initial activation of DCs and/or NK cells, thereby increasing DC-dependent adaptive (cellular) immune responses (46–50). Our data suggest that harnessing this potential capability of NKT cells (in this instance via expression of EAT-2) may be an important goal of “next-generation” vaccines.

Previous reports have shown that SLAM-derived signaling can also increase the Ag-presentation capabilities of APCs (18, 19). We note that EAT-2 is the only SLAM adapter molecule currently known to be expressed in APCs (16). These previous observations suggest that Ad-mediated transduction of EAT-2 into DCs may have directly facilitated the induction of Ag-specific adaptive immune responses observed in this study. We confirmed that EAT-2 overexpression within several different types of APC triggers the induction of CD40, CD80, CD86, and MHC class II, all of which are critical costimulatory molecules that augment subsequent APC activation of T cells. Although it is known that Ads can transduce APCs and DCs in vivo, other cell types may also be transduced by the Ad vector expressing EAT-2 and also be affecting our in vivo results. It is conceivable that EAT-2 overexpression also facilitated SLAM-independent functions in Ad-EAT2–transduced immune cells. SAP family adapters can also interact, by way of their SH2 domain, with other classes of receptors expressed in immune cells including CD22 (expressed in both CD8α DCs and B cells) and FCyRIII (51, 52). Future studies will be required to delineate which aspects of the augmented EAT-2–dependent immune responses may be mediated by these or other receptors.

Various studies in mouse models and non-human primates suggest that improving the breadth of the Ag-specific cellular immune responses elicited by a vaccine is positively correlated with an improved ability of the vaccine to induce protective immunity, for example after pathogen challenge of vaccinated subjects (53, 54). Our results demonstrate that vaccine mixtures possessing the ability to express EAT-2 along with a target Ag increased the breadth of the cellular immune responses to the Ag, a result that correlated with a significantly improved induction of Ag-specific cytolytic T cell activity in vivo. We confirmed these results in both C57BL/6 and BALB/c mice (two mouse strains that can bias adaptive immune responses to a Th1 or Th2 response, respectively) indicating that the “adjuvant” effect of EAT-2 is not specifically limited by immunogenetic background differences of the host animal, at least in this species. In conclusion, our findings suggest that enhancing SLAM signaling by expressing EAT-2 during Ag vaccination can serve to improve the ability of a vaccine to stimulate the innate immune system and subsequently induce improved, Ag-specific adaptive immune responses.

Acknowledgments

We thank Michigan State University laboratory animal support facilities for assistance in the humane care and maintenance of the animals used in this work. We specifically thank Dr. Sungjin Kim for generous advice and suggestions.

Disclosures

The authors have no financial conflicts of interest.

References


13. Veillette, A. 2006. Immunology regulation by SLAM family receptors and SAP-


16. Veillette, A. 2006. NK cell regulation by SLAM family receptors and SAP-


19. Pulenhorst, B., and R. Ahmed. 2006. Translating innate immunity into immuno-


